How "research-only" peptides reach 40,000 European customers a month

This is the first instalment in a four-part series. The opening piece focuses on a single Rotterdam pharmacy and the broker that sources its raw materials.

Three of the seven products we tested contained less than 60% of the labelled peptide content. Two contained a different compound altogether.

Subsequent parts examine the EU’s compounding exemption, the German §13 AMG loophole, and the role of online “telehealth” prescribers.